# 6ì£¼ ì‹¤í–‰ Timeline

## Paper A / Paper B ë²”ìœ„ í‘œì‹œ

```
ğŸ“˜ = Paper B ë²”ìœ„ (100 studies, AI vs. Human ë¹„êµ)
ğŸ“— = Paper A ë²”ìœ„ (ì „ì²´ ~300 studies, MASEM ë°ì´í„°)
ğŸ“˜ğŸ“— = ì–‘ìª½ ëª¨ë‘ í•´ë‹¹
```

## ì „ì²´ ì¼ì •

```
Week 1 â”€â”€â”€â”€ Setup + Full-text Review + AI Extraction     ğŸ“˜ğŸ“—
Week 2 â”€â”€â”€â”€ Phase 1: Independent Human Coding (ì‹œì‘)      ğŸ“˜ğŸ“—
Week 3 â”€â”€â”€â”€ Phase 1: Coding ì™„ë£Œ + IRR + Gold Standard   ğŸ“˜ğŸ“—
Week 4 â”€â”€â”€â”€ Phase 1 ë¶„ì„ ğŸ“˜ + Phase 2 ì‹œì‘ ğŸ“—
Week 5 â”€â”€â”€â”€ Phase 2 ì™„ë£Œ + Phase 3 QA ğŸ“— + Paper B ì‘ì„± ğŸ“˜
Week 6 â”€â”€â”€â”€ Paper B ì™„ì„± ğŸ“˜ + Data Freeze ğŸ“—
```

---

## Week 1: Setup + Full-text Review + AI Extraction ğŸ“˜ğŸ“—

| Day | ì‘ì—… | ë‹´ë‹¹ | ì‚°ì¶œë¬¼ | ë²”ìœ„ |
|-----|------|------|--------|------|
| 1-2 | Full-text PDF ìˆ˜ì§‘ (575ê°œ) | H1 | PDFs | ğŸ“˜ğŸ“— |
| 1-2 | Full-text eligibility review ì‹œì‘ | H1 | â€” | ğŸ“˜ğŸ“— |
| 3 | Calibration session (H1+H2, pilot 10ê°œ) | H1, H2 | Pilot IRR | ğŸ“˜ğŸ“— |
| 3-5 | Full-text eligibility review ì™„ë£Œ | H1 | fulltext_eligibility_decisions.csv | ğŸ“˜ğŸ“— |
| 5 | MASEM-eligible ~300ê°œ í™•ì • | H1 | eligible list | ğŸ“˜ğŸ“— |
| 5 | 100-study stratified sample ì¶”ì¶œ | H1 | paper_b_sample_100.csv | ğŸ“˜ |
| 5-7 | 3 AI models extract 100 studies | Pipeline | 02_ai_extraction/ | ğŸ“˜ |
| 5-7 | 3 AI models extract ë‚˜ë¨¸ì§€ ~200 studies | Pipeline | 02_ai_extraction/ | ğŸ“— |
| 6-7 | H2: 30% full-text IRR sample ë…ë¦½ review | H2 | fulltext_irr_sample.csv | ğŸ“˜ğŸ“— |

## Week 2: Phase 1 â€” Independent Human Coding ğŸ“˜ğŸ“—

| Day | ì‘ì—… | ë‹´ë‹¹ | Pace | ë²”ìœ„ |
|-----|------|------|------|------|
| 1-5 | 100 studies ë…ë¦½ ì½”ë”© | H1 | 20/day | ğŸ“˜ğŸ“— |
| 1-5 | 100 studies ë…ë¦½ ì½”ë”© | H2 | 20/day | ğŸ“˜ğŸ“— |

**Daily target**: ê°ì 20 studies/day Ã— 5 days = 100 studies
**ì˜ˆìƒ ì†Œìš”**: ~30-45 min/study Ã— 20 = 10-15 hours/day (intensive)
**í•µì‹¬**: H1, H2 ëª¨ë‘ AI outputì— blinded ìƒíƒœ ìœ ì§€

## Week 3: Phase 1 â€” IRR + Gold Standard ğŸ“˜ğŸ“—

| Day | ì‘ì—… | ë‹´ë‹¹ | ì‚°ì¶œë¬¼ | ë²”ìœ„ |
|-----|------|------|--------|------|
| 1-2 | ì½”ë”© ì™„ë£Œ + ì œì¶œ | H1, H2 | coder1_PI/, coder2_phd1/ | ğŸ“˜ğŸ“— |
| 2-3 | **Unblinding**: IRR ê³„ì‚° | H1 | irr_results.csv | ğŸ“˜ |
| 3-4 | Discrepancy identification | H1 | discrepancy_log.csv | ğŸ“˜ğŸ“— |
| 4-5 | Discrepancy resolution meeting | H1, H2 | resolved values | ğŸ“˜ğŸ“— |
| 5 | Gold standard finalization | H1 | gold_standard_100.csv | ğŸ“˜ğŸ“— |

## Week 4: Paper B ë¶„ì„ ğŸ“˜ + Phase 2 ì‹œì‘ ğŸ“—

| Day | ì‘ì—… | ë‹´ë‹¹ | ì‚°ì¶œë¬¼ | ë²”ìœ„ |
|-----|------|------|--------|------|
| 1 | AI consensus ê³„ì‚° (100 studies) | H1 | consensus_100.csv | ğŸ“˜ |
| 1-2 | RQ1-4 ë¶„ì„ ì‹¤í–‰ | H1 | model_accuracy.csv ë“± | ğŸ“˜ |
| 3-5 | AI consensus ê²€ì¦ (~200 studies) | H1 | ~100 studies | ğŸ“— |
| 3-5 | AI consensus ê²€ì¦ (~200 studies) | H2 | ~100 studies | ğŸ“— |

**Phase 2 pace**: ê°ì 20 studies/day (verification mode, ë…ë¦½ ì½”ë”©ë³´ë‹¤ ë¹ ë¦„)

## Week 5: Phase 2 ì™„ë£Œ ğŸ“— + Paper B ì‘ì„± ğŸ“˜

| Day | ì‘ì—… | ë‹´ë‹¹ | ì‚°ì¶œë¬¼ | ë²”ìœ„ |
|-----|------|------|--------|------|
| 1-2 | Phase 2 verification ì™„ë£Œ | H1, H2 | verified_data_phase2.csv | ğŸ“— |
| 1-2 | Paper B Tables 5-10 ì±„ìš°ê¸° | H1 | Results section | ğŸ“˜ |
| 2-3 | Figures ìƒì„± (heatmap, Bland-Altman) | H1 | figures/ | ğŸ“˜ |
| 3-4 | H3: 10% spot-check (~20 studies) | H3 | qa_spotcheck.csv | ğŸ“— |
| 4-5 | QA gates í™•ì¸ | H1 | qa_report.md | ğŸ“— |

## Week 6: Paper B ì™„ì„± ğŸ“˜ + Data Freeze ğŸ“—

| Day | ì‘ì—… | ë‹´ë‹¹ | ì‚°ì¶œë¬¼ | ë²”ìœ„ |
|-----|------|------|--------|------|
| 1-2 | Paper B Discussion + Conclusion | H1 | ë…¼ë¬¸ v2.0 | ğŸ“˜ |
| 2-3 | PRISMA-trAIce + TRIPOD-LLM ì™„ì„± | H1 | checklists/ | ğŸ“˜ |
| 3-4 | ë‚´ë¶€ ê²€í†  | H1, H2 | í”¼ë“œë°± | ğŸ“˜ |
| 5 | Data finalization (ì „ì²´ ~300) | H1 | ì „ì²´ ë°ì´í„° í™•ì • | ğŸ“— |
| 6-7 | OSF ë“±ë¡ (prompts, data, code) | H1 | OSF project | ğŸ“˜ğŸ“— |

---

## Milestones & Checkpoints

| Week | Milestone | ì„±ê³µ ê¸°ì¤€ | ë²”ìœ„ |
|------|-----------|----------|------|
| W1 | Full-text eligibility ì™„ë£Œ | ~300 MASEM-eligible studies í™•ì • | ğŸ“˜ğŸ“— |
| W1 | 100-study sample í™•ì • | Stratified sample ì¶”ì¶œ ì™„ë£Œ | ğŸ“˜ |
| W1 | AI extraction ì™„ë£Œ (100) | 3 models Ã— 100 studies JSON ìƒì„± | ğŸ“˜ |
| W1 | Calibration í†µê³¼ | Pilot Îº â‰¥ 0.80, ICC â‰¥ 0.85 | ğŸ“˜ğŸ“— |
| W3 | Phase 1 IRR í™•ì¸ | Îº â‰¥ 0.85, ICC â‰¥ 0.90 | ğŸ“˜ |
| W3 | Gold standard í™•ì • | 100 studies Ã— 30 variables resolved | ğŸ“˜ğŸ“— |
| W4 | Paper B ë¶„ì„ ì™„ë£Œ | RQ1-4 ì‹¤í–‰ | ğŸ“˜ |
| W5 | Phase 2 ì™„ë£Œ | ~200 studies verified | ğŸ“— |
| W5 | QA spot-check í†µê³¼ | Error rate < 5% | ğŸ“— |
| W6 | Paper B draft v2.0 | Results + figures ì™„ì„± | ğŸ“˜ |
| W6 | Data freeze | ì „ì²´ ~300 studies í™•ì • | ğŸ“— |

---

## Risk Mitigation

| ë¦¬ìŠ¤í¬ | í™•ë¥  | ëŒ€ì‘ | ì˜í–¥ |
|--------|------|------|------|
| Full-text ì ‘ê·¼ ë¶ˆê°€ (>10%) | ì¤‘ | ILL ì¡°ê¸° ìš”ì²­, ì €ì ì—°ë½ | ğŸ“˜ğŸ“— |
| Calibration ì‹¤íŒ¨ (Îº < 0.80) | ë‚® | ì¶”ê°€ training session, pilot 5ê°œ ì¶”ê°€ | ğŸ“˜ğŸ“— |
| Phase 1 IRR ë¯¸ë‹¬ | ë‚® | ì½”ë”© ê·œì¹™ ëª…í™•í™”, 10ê°œ ì¬ì½”ë”© | ğŸ“˜ |
| AI extraction pipeline ì˜¤ë¥˜ | ì¤‘ | Week 1ì— 10ê°œ test run ì„ í–‰ | ğŸ“˜ |
| Phase 2 ì¼ì • ì§€ì—° | ì¤‘ | Phase 2 volume ì¡°ì •, ìš°ì„ ìˆœìœ„ ì¬ë°°ì • | ğŸ“— |
| Paper B ì‘ì„± ì§€ì—° | ë‚® | Week 4-5 ë¶„ì„/ì‘ì„± ë³‘í–‰ | ğŸ“˜ |
